Gary Foster, MD
Ophthalmology · Fort Collins, CONPI 1730185182
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,710 of the $74,741 with a category attached, or 70.5%. Alcon accounts for 81.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $25,990 and has fallen 90.3% since, to $2,514 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $373.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$61K
- Alcon Research LLC$6K
- Rayner Intraocular Lenses Limited$3K
- Eyevance Pharmaceuticals LLC$1K
- Glaukos Corporation$600
- Rxsight Inc$449
- plus $2K from 21 others
Across 390 payments — averaging $964.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$340K
- Bausch & Lomb Americas Inc.$19K
- Rxsight Inc$9K
- Ivantis, Inc$6K
- Bausch Health US, LLC$2K
What the payments were for
- Consulting fees$52,71071%
- Speaking & faculty fees$11,23615%
- Travel & lodging$3,3274%
- Food & beverage$7,46610%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 95 | $60,887 |
| Alcon Research LLC | 3 | $6,128 |
| Rayner Intraocular Lenses Limited | 4 | $2,824 |
| Eyevance Pharmaceuticals LLC | 5 | $1,455 |
| Glaukos Corporation | 5 | $600 |
| Rxsight Inc | 7 | $449 |
| NEW World Medical,inc. | 16 | $423 |
| Bausch & Lomb Americas Inc. | 10 | $275 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $202 |
| Sun Pharmaceutical Industries Inc. | 5 | $200 |
| Kala Pharmaceuticals, Inc. | 8 | $165 |
| Tarsus Pharmaceuticals, Inc. | 4 | $164 |
| Ocular Therapeutix, Inc. | 1 | $148 |
| AbbVie(2 entities) | 8 | $135 |
| Lensar, Inc. | 2 | $115 |
| Sight Sciences, Inc. | 4 | $112 |
| Carl Zeiss Meditec USA, Inc. | 1 | $88 |
| Ivantis, Inc | 1 | $63 |
| Novartis | 3 | $63 |
| Carl Zeiss Meditec, Inc. | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 3 | $50 |
| Omeros Corporation | 3 | $45 |
| Dompe US, Inc. | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Harrow Eye, LLC | 1 | $18 |
| Thea Pharma Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$31,232
- Clareon$12,912
- AcrySof IQ VIVITY IOL$7,809
- AcrySof IQ VIVITY$3,500
- AcrySof IQ PanOptix UV IOL$3,500
- AcrySof IQ PanOptix$2,800
- OMIDRIA$2,300
- Centurion$1,500
- Wavelight Refractive Suite$1,500
- Flarex$1,351
- Hydrus Microstent$930
- NGENUITY$795
- AcrySof$700
- ORA System VerifEye$651
- Unity$241
- RXSIGHT CONTACT LENS$232
- RXSIGHT INJECTOR CARTRIDGE$232
- RXSIGHT INJECTOR HANDPIECE$232
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$232
- iDoseTR$211
How this compares
$74,741 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $16,549 |
| ProlensaBromfenac Sodium | 40 | $13,800 |
| Prednisolone Acetate | 377 | $11,007 |
| Bromfenac Sodium | 51 | $10,192 |
| Restasis MultidoseCyclosporine | 11 | $7,083 |
| Ketorolac Tromethamine | 258 | $5,793 |
| MoxifloxacinMoxifloxacin Hcl | 209 | $4,786 |
| Ofloxacin | 160 | $1,980 |
| Latanoprost | 24 | $454 |
| Tobramycin | 20 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $135 | $23,63229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Fort Collins
- Jason MayerFort Collins$42K
- Karl OlsenFort Collins$15K
- Brittney StatlerFort Collins$8K
- Matthew AsanoFort Collins$4K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.